F. Garzon

Statistics

Publications

Citations

170

H-Index

Active since

2008

Affiliations

Novartis (United States)(Current)

F. Garzon is an author at Novartis (United States) specializing in tyrosine kinase inhibitors, cancer pharmacology, and tyrosine kinase inhibitor therapy.

Publications per year

2008–2014

Publications

A Phase I Pharmacokinetic and Pharmacodynamic Study of TKI258, an Oral, Multitargeted Receptor Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors

Debashis Sarker, R. Molife, T. R. J. Evans et al. · Clinical Cancer Research · 2008 · 137 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

Clonal Expansion of T/NK-Cells during Tyrosine Kinase Inhibitor Dasatinib Therapy

Satu Mustjoki, Marja Ekblom, T. Petteri Arstila et al. · Blood · 2008 · 21 citations

Life Sciences, Immunology, Oncology +14

Randomized phase II study of two intercalated combinations of eribulin mesylate and erlotinib in patients with previously treated advanced non-small-cell lung cancer

Tony Mok, Sarayut Lucien Geater, Nicholas Iannotti et al. · Annals of Oncology · 2014 · 12 citations · Full text

Medicine, Oncology, Pharmacology +11

1–3 of 3